QUIT · Achieve Life Sciences, Inc. · Metrics
$5.73
-0.15 (-2.47%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Market Cap
$645.90M
Shares
110.03M
Volume · Nov 20
693.7K
Avg daily vol (3M)
1.37M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
QUIT metrics
37 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$5.87
Market cap
$645.90M
Price action
23 metricsPrice change (1W)
—
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
89.0%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
110.03M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.6
reciprocal yield 28.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-17.3%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-11
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
−$111.71M
Trailing 12 months
Diluted EPS (TTM)
$-1.33
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+106.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-61.8%
Return on assets
-54.1%
Debt / equity
—
Current ratio
10.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
10.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$201.52M
Latest balance sheet
Cash & equivalents
$59.74M
Total assets
$206.42M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$44.04M
Capital expenditures (TTM)
—
R&D (TTM)
$26.42M
SG&A (TTM)
—
Stock compensation (TTM)
$15.28M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
132
13F filer change QoQ
+20
Institutional ownership
89.0%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
54.0%
Private-fund adviser ownership
53.4%
Active holders' share change QoQ
+22.3%
Holder tenure
5.4
Price vs estimated holder cost
+54.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
8.7%
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—